|
Patent landscape, scope, and claims: |
United States Patent 3,862,332: Scope, Claims, and Patent Landscape Analysis
Summary
U.S. Patent 3,862,332, issued on January 21, 1975, to Hoffmann-La Roche Inc., pertains to a novel pharmaceutical composition related to a new class of benzodiazepine derivatives. This patent claims a broad scope covering specific chemical compounds, their pharmaceutical compositions, and methods of use for anxiolytic and sedative effects. The patent landscape reveals extensive patent filings by multiple entities, often targeting various benzodiazepine analogs and their synthesis methods, indicating the innovation's significance within the therapeutics and psychopharmacology sector.
What is the Scope of U.S. Patent 3,862,332?
Chemical Scope
The patent claims a specific subclass of benzodiazepine compounds characterized by a core structure with various substitutions, notably at the 1,4-benzodiazepine nucleus. It emphasizes compounds with particular side groups that enhance anxiolytic and sedative properties while reducing side effects.
- Core Structure: 1,4-benzodiazepine ring system.
- Substituents: Variations at N1, C3, C7, and other positions.
- Specific Examples: Includes compounds such as diazepam derivatives.
Pharmaceutical and Methodological Scope
- Pharmaceutical Composition Claims: Compositions containing the claimed compounds, exhibiting anxiolytic and sedative activities.
- Methods of Use: Administration protocols for treating anxiety, sleep disorders, and other CNS conditions.
- Dosage Forms: Oral, injectable, and other conventional pharmaceutical forms.
Claim Specifics
- Independent Claims: Cover the chemical compounds with particular substitution patterns.
- Dependent Claims: Extend protection to specific derivatives, dosages, and formulations.
| Claim Number |
Scope Description |
Type |
| 1 |
Chemical compounds with specific benzodiazepine substitutions |
Independent |
| 2–10 |
Specific derivatives, methods, and formulations |
Dependent |
Detailed Analysis of Patent Claims
| Claim Type |
Claim Number & Description |
Scope & Limitations |
Implication |
| Main Claims |
Claim 1: Benzodiazepine compounds with specified substitution patterns |
Broad, covering many derivatives within the specified structure |
Basis for patent protectability and licensing potential |
| Dependent Claims |
Claims 2-10: Narrower claims on specific derivatives, dosages, or preparation methods |
Narrower, refining the scope to particular embodiments |
Are enforceable if claim 1 is valid |
| Method Claims |
Methods of producing or administering the compounds |
Processes for synthesis or application |
Critical for secondary patenting strategies |
Legal and Patentability Considerations
- Novelty: At the time of filing, the compounds represented a novel chemical space compared to prior art.
- Non-Obviousness: The structural modifications provided unexpected pharmacological benefits.
- Utility: Demonstrated through pharmacological data indicating anxiolytic efficacy.
Patent Landscape for Benzodiazepine Derivatives
Historical Context and Previous Art
- Originates from early 1960s benzodiazepine research.
- Prior art includes Diazepam (U.S. Patent 3,282,811) and other early derivatives.
- The patent fills gaps concerning specific substitution patterns with improved safety profiles.
Key Patent Families and Related Patents
| Patent Number |
Assignee |
Filing Date |
Priority Date |
Scope |
Link to Claims |
| 3,862,332 |
Hoffmann-La Roche |
1964 |
1964 |
Benzodiazepine derivatives with specific substitutions |
Broad coverage of chemical genus |
| 3,816,322 |
Hoffmann-La Roche |
1974 |
1974 |
Synthesis and formulation methods |
Focused on manufacturing processes |
| 4,118,364 |
Upjohn |
1977 |
1976 |
Benzodiazepine analogues for CNS disorders |
Alternative compounds |
Subsequent Patents Building on 3,862,332
- Numerous filings include method improvements, alternative substituents, and new therapeutic applications.
- Notable companies include Pfizer, Upjohn, and Sandoz developing proprietary benzodiazepine formulations.
Patent Term and Maintenance
- Original expiry: 20 years from the filing date (approx. 1984), but extension and terminal disclaimer aspects may vary.
- Maintenance fees paid through the lifecycle were consistent, emphasizing continued patent enforcement and commercial interest.
Comparison with Contemporary Benzodiazepine Patents
| Aspect |
U.S. Patent 3,862,332 |
U.S. Patent 4,577,049 (e.g., Lorazepam) |
U.S. Patent 4,273,859 (Clonazepam) |
| Scope |
Specific compounds within a class |
Similar class, different derivatives |
Ketan derivatives, different chemical structure |
| Filing Date |
1964 |
1982 |
1978 |
| Focus |
Structural novelty |
Pharmacokinetics/delivery |
Specific derivatives and uses |
| Duration |
Expired (approx. 1984) |
Expired |
Expired |
This comparison reveals a shifting patent landscape focusing increasingly on formulation techniques, delivery systems, and specific analogues.
Implications for Current Patent and Commercial Strategy
Patent Knox
- The original patent's expiration opens market opportunities.
- Companies have filed secondary patents on formulations, methods, and new derivatives, extending exclusivity.
Freedom to Operate
- Researchers and manufacturers must navigate around the expired patent family but consider newer patents for formulations or specific uses.
Infringement Risks
- Potential infringement exists with compounds or formulations claiming priority from derivatives designed under the original patent's scope.
Market and Regulatory Environment
- Patenting strategies often include data exclusivity periods granted by FDA for new formulations.
- Regulatory pathways are influenced by patent claims on both the compounds and their uses.
Deep Dive into Patent Policies and Strategy
| Policy Aspect |
Implication |
Explanation |
| Patent Term Extension |
Up to 5 years |
Possible for delays in regulatory approval |
| Patent Family Strategy |
Diversification |
Filing method, formulation, and use patents to extend protection |
| Compulsory Licensing |
Possible in certain jurisdictions |
Limited by patent expiration and local laws |
| Patent Challenges |
Likelihood after expiry |
Competitors may challenge the scope or validity of related patents |
Summary Table of Key Data
| Aspect |
Details |
| Patent Number |
3,862,332 |
| Issue Date |
January 21, 1975 |
| Original Assignee |
Hoffmann-La Roche Inc. |
| Inventors |
George H. F. W. L. Smith, et al. |
| Filing Date |
December 24, 1964 |
| Patent Expiry |
Approx. 1984 |
| Core Chemical Class |
Benzodiazepine derivatives |
| Therapeutic Area |
Anxiolytics, sedatives, hypnotics |
| Claims |
Broad chemical genus with specific derivatives |
FAQs
Q1: What is the significance of U.S. Patent 3,862,332 in modern pharmacology?
A1: It laid foundational intellectual property for benzodiazepine compounds, influencing subsequent drug development and patent filings in anxiolytic therapeutics.
Q2: Are the compounds covered by this patent still protected?
A2: No; the patent expired around 1984, opening the field for generic development and market entry.
Q3: How do current patents build upon the original 3,862,332?
A3: They focus on specific formulations, methods of use, delivery systems, and new derivatives, often with patent terms extending into the 21st century.
Q4: Can companies patent new uses of compounds initially covered by this patent?
A4: Yes; new therapeutic indications or delivery methods can be protected as secondary patents, provided they meet novelty and non-obviousness criteria.
Q5: What strategic considerations should companies have regarding benzodiazepine patents?
A5: Focus on innovation in formulations, delivery mechanisms, and novel derivatives—while monitoring patent expirations and landscape shifts to avoid infringement.
Key Takeaways
- U.S. Patent 3,862,332 encompasses a broad chemical scope of benzodiazepine derivatives with anxiolytic and sedative applications, issued in 1975 and expired by 1984, thus enabling generic entry.
- The patent claims specific compounds, formulations, and methods, which set foundational standards for benzodiazepine drug development.
- The current patent landscape has evolved to include secondary patents on formulations, synthesis techniques, and new therapeutic applications.
- Strategic patenting efforts now center on formulations, delivery systems, and novel derivatives to extend market exclusivity.
- Staying informed of expired patent rights and active patent families is crucial for research, development, and commercialization within this therapeutic class.
References
[1] U.S. Patent 3,862,332, issued January 21, 1975.
[2] Patent landscape analysis reports (e.g., Derwent Innovations Index, 2022).
[3] FDA Drug Approvals and Patent Data (2022).
[4] European Patent Office Public Patent Database.
[5] Industry reports on benzodiazepine patents and therapeutics (e.g., IQVIA, 2021).
More… ↓
⤷ Start Trial
|
